Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation after first-line R-CVP in PET-positive partial remission follicular lymphoma
NL-OMON28762Phase 2Not yet recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Aug 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Conversion rate from partial remission to complete remission. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON28762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28762.